



RE: Discontinuation of Elspar[®], (asparaginase for injection) 10,000 IU

Dear Healthcare Provider:

This letter is intended to inform you that Lundbeck will be discontinuing the sale of Elspar[®] in the US by the end of December 2012. This action is not the result of any safety or efficacy issues regarding this product.

Since acquiring Elspar[®] in 2006, Lundbeck has continued to work diligently to secure a new supply chain for the product; however, this process has been challenging. We have invested significant resources transferring the formulation to a new drug product source and developing new analytical procedures to comply with current FDA/GMP/ICH standards. Despite our diligent efforts, we have continued to experience periodic supply interruptions which have often required short-term product allocations.


Recent development activities have led us to the conclusion that securing future long-term sourcing for the active substance and the drug product would require additional investment and significant changes to underlying processes and specifications. Global regulatory acceptance of such changes would be highly uncertain; and therefore, Lundbeck is no longer in a position to guarantee a future supply.

Due to these ongoing manufacturing challenges, and knowing that other asparaginase products are available in the US and most other markets, Lundbeck has concluded that continuing to manufacture and distribute Elspar is not a sustainable business going forward. Therefore, Lundbeck has decided to exit all markets globally; and we plan to discontinue Elspar in the US effective December 31, 2012. However, this date may be advanced or deferred slightly depending on our remaining inventory of product.


We ask that wholesaler customers and healthcare providers allocate their remaining product inventory for human use so current patients may conclude treatment protocols involving Elspar during this transition period. To facilitate the transition and prioritization process, our final inventory will be allocated based on historical demand and closely monitored.

Patients and customers in the U.S. should continue to have access to other forms of asparaginase, and as such, are encouraged to consult with healthcare providers or centers of excellence to discuss other available treatment options that may be appropriate. If you require additional information, please contact 1-888-514-5204.

Thank you for your understanding.



Roger Keding
Vice President, Supply Chain Management



Date